A method for the synthesis of a heterocyclic hydrogen phosphine oxide, having the general formula:

##STR00001##

wherein:
R is a aliphatic or aromatic divalent group optionally including one or more heteroatoms and optionally having one or more substituents and
X and Y are independently selected from —O—, —C(O)O— and —NR′—
wherein R′ is a monovalent group optionally having one or more heteroatoms including the steps of:
a) forming a reaction mixture by mixing a compound having the general formula HX—R—YH and tetraphosphorus hexaoxide; and
b) recovering the resulting compound comprising the heterocyclic hydrogen phosphine oxide.

The present invention includes a multi-layer 3D material, a method of making, and a catalyst comprising: a first, a second, and a third layer, wherein each of the layers are arranged in a nearly parallel fashion with chirality along a center plane.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

Provided herein are cyclic plasmenylethanolamines and plasmalogen precursors of formula A, wherein R.sub.1 and R.sub.2 are each, independently, a saturated, unsaturated, or polyunsaturated hydrocarbon group. Methods and uses thereof in the treatment of plasmalogen deficiency are also described. Cyclic plasmenylethanolamines described herein may act as plasmalogen precursors which, following administration, may be converted to at least one plasmalogen species, thereby elevating the plasmalogen level in a subject. ##STR00001##

Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with Mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with Mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.

Ligands for use with catalyst compositions used in hydroformylation reactions are described herein. The ligands are used with various solvents and achieve an increase in isoselectivity with an increase in temperature.

The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.